Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1α inactivation in hypoxic PC-3 prostate cancer cells

Journal of Pineal Research

Volumn 51, Issue 1, 2011, Pages 87-93

  Cho, Sung Yun ^a   Lee, Hyo Jeong ^a   Jeong, Soo Jin ^a   Lee, Hyo Jung ^a   Kim, Hyun Seok ^b   Chen, Chang Yan ^c   Lee, Eun Ok ^a   Kim, Sung Hoon ^a  

^a Kyung Hee University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AKT; hypoxia inducible factor 1 ; melatonin; sphingosine kinase 1; vascular endothelial growth factor

Indexed keywords

ACETYLCYSTEINE; GLYCOGEN SYNTHASE KINASE 3BETA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MELATONIN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; SPHINGOSINE KINASE 1; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STABILITY; HYPOXIA; MALE; NONHUMAN; PHOSPHORYLATION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

CELL HYPOXIA; CELL LINE, TUMOR; GENE EXPRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MELATONIN; METABOLIC NETWORKS AND PATHWAYS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; STATISTICS, NONPARAMETRIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960344288     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2011.00865.x     Document Type: Article

References (40)

1. Hockel M, Vaupel P,. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-276. (Pubitemid 32219813)
2. Welsh SJ, Koh MY, Powis G,. The hypoxic inducible stress response as a target for cancer drug discovery. Semin Oncol 2006; 33: 486-497. (Pubitemid 44142742)
3. Semenza GL,. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 2004; 5: 405-406. (Pubitemid 38610240)
4. Semenza GL,. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732. (Pubitemid 37328811)
5. Pouyssegur J, Dayan F, Mazure NM,. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441: 437-443. (Pubitemid 44050138)
6. Jeong JW, Bae MK, Ahn MY, et al., Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002; 111: 709-720.
7. Wang GL, Semenza GL,. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270: 1230-1237.
8. Schofield CJ, Ratcliffe PJ,. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5: 343-554.
9. Melillo G,. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 2007; 26: 341-352. (Pubitemid 47101663)
10. Spiegel S, Milstien S,. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003; 4: 397-407. (Pubitemid 36565571)
11. Cuvillier O, Pirianov G, Kleuser B, et al., Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996; 381: 800-803. (Pubitemid 26243122)
12. Anelli V, Gault CR, Cheng AB, et al., Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2. J Biol Chem 2008; 283: 3365-3375.
13. Cuvillier O,. Downregulating sphingosine kinase-1 for cancer therapy. Expert Opin Ther Targets 2008; 12: 1009-1020.
14. Visentin B, Vekich JA, Sibbald BJ, et al., Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006; 9: 225-238. (Pubitemid 43357948)
15. Reiter RJ,. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12: 151-180.
16. Reiter RJ, Paredes SD, Manchester LC, et al., Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009; 44: 175-200.
17. Reiter RJ,. The melatonin rhythm: both a clock and a calendar. Experientia 1993; 49: 654-664. (Pubitemid 23256791)
18. Gitto E, Pellegrino S, Gitto P, et al., Oxidative stress of the newborn in the pre- and postnatal period and the clinical utility of melatonin. J Pineal Res 2009; 46: 128-139.
19. Hardeland R,. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 2005; 27: 119-130. (Pubitemid 41558444)
20. Joo SS, Yoo YM,. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. J Pineal Res 2009; 47: 8-14.
21. Jung-Hynes B, Huang W, Reiter RJ, et al., Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res 2010; 49: 60-68.
22. Jung-Hynes B, Reiter RJ, Ahmad N,. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res 2010; 48: 9-19.
23. Dai M, Cui P, Yu M, et al., Melatonin modulates the expression of VEGF and HIF-1 alpha induced by CoCl2 in cultured cancer cells. J Pineal Res 2008; 44: 121-126. (Pubitemid 351252913)
24. Park JW, Hwang MS, Suh SI, et al., Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells. J Pineal Res 2009; 46: 415-421.
25. Park SY, Jang WJ, Yi EY, et al., Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. J Pineal Res 2010; 48: 178-184.
26. Park KY, Lee HJ, Jeong SJ, et al., 1,2,3,4,6-Penta-O-galloly-beta-D- glucose suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and signaling in LNCaP prostate cancer cells. Biol Pharm Bull 2010; 33: 1835-18400.
27. Ahn Q, Jeong SJ, Lee HJ, et al., Inhibition of cyclooxygenase-2-dependent survivin mediates decursin-induced apoptosis in human KBM-5 myeloid leukemia cells. Cancer Lett 2010; 298: 212-221.
28. Ferrara N, Gerber HP, Lecouter J,. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676. (Pubitemid 36749215)
29. Xia C, Meng Q, Liu LZ, et al., Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 2007; 67: 10823-10830. (Pubitemid 350145911)
30. Smith TG, Robbins PA, Ratcliffe PJ,. The human side of hypoxia-inducible factor. Br J Haematol 2008; 141: 325-334. (Pubitemid 351521147)
31. Cuvillier O, Ader I, Bouquerel P, et al., Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Curr Mol Pharmacol 2010; 3: 53-65.
32. Pitman MR, Pitson SM,. Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr Cancer Drug Targets 2010; 10: 354-367.
33. Ader I, Malavaud B, Cuvillier O,. When the sphingosine kinase 1/sphingosine 1-phosphate pathway meets hypoxia signaling: new targets for cancer therapy. Cancer Res 2009; 69: 3723-3726.
34. Tao R, Zhang J, Vessey DA, et al., Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res 2007; 74: 56-63. (Pubitemid 46366955)
35. Pchejetski D, Kunduzova O, Dayon A, et al., Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res 2007; 100: 41-49. (Pubitemid 46066772)
36. Ader I, Brizuela L, Bouquerel P, et al., Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res 2008; 68: 8635-8642.
37. Gariboldi MB, Ravizza R, Monti E,. The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol 2008; 80: 455-462.
38. Giatromanolaki A, Fiska A, Pitsiava D, et al., Erythropoietin receptors in endometrial carcinoma as related to HIF1{alpha} and VEGF expression. In Vivo 2009; 23: 699-703.
39. Shankar J, Thippegowda PB, Kanum SA,. Inhibition of HIF-1alpha activity by BP-1 ameliorates adjuvant induced arthritis in rats. Biochem Biophys Res Commun 2009; 387: 223-228.
40. Yao H, Wang H, Zhang Z, et al., Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells. Int J Cancer 2008; 123: 1255-1261.